Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
01 févr. 2024 08h00 HE
|
Ardelyx, Inc.
WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx, Inc. Reports Employment Inducement Grants
12 janv. 2024 07h56 HE
|
Ardelyx, Inc.
WALTHAM, Mass., Jan. 12, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
08 janv. 2024 08h00 HE
|
Ardelyx, Inc.
Company achieved significant commercial progress in 2023 IBSRELA® now expected to generate greater than $1.0 billion in annual U.S. net product sales revenue at peak Webcast scheduled for 7:00 PM ET...
Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
03 janv. 2024 08h03 HE
|
Ardelyx, Inc.
WALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx, Inc. Reports Employment Inducement Grants
20 déc. 2023 08h00 HE
|
Ardelyx, Inc.
WALTHAM, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx, Inc. Reports Employment Inducement Grants
21 nov. 2023 16h02 HE
|
Ardelyx, Inc.
WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
21 nov. 2023 08h01 HE
|
Ardelyx, Inc.
WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
15 nov. 2023 16h02 HE
|
Ardelyx, Inc.
WALTHAM, Mass., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx Announces Departure of Board Member
13 nov. 2023 16h02 HE
|
Ardelyx, Inc.
WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx to Participate at the Jefferies London Healthcare Conference
10 nov. 2023 08h05 HE
|
Ardelyx, Inc.
WALTHAM, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...